M&A: Week 13
In this week's M&A review In this week's M&A review * Softbank to acquire Ampere Computing in US$ 6.5 billion deal * Google to acquire Wiz - the company's most expensive deal to date Softbank to acquire Ampere Computing in US$
More issues
Cortigent’s Patent Portfolio: Aging IP or Strategic Reset?
Vivani Medical has announced plans to spin off Cortigent as an independent publicly-traded company. The spin-off is planned to be completed by Q3 2025.
Vivani Medical was formed in 2022 through the merger of Second Sight Medical and Nano Precision Medical. Cortigent, previously known as Second Sight Medical Products, has
M&A: Week 12
In this week's M&A review
* 2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal
2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal
2Seventybio has announced a definitive merger agreement under which Bristol Myers
M&A: Week 11
In this week's M&A review
* Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash
Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash
Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant
M&A: Week 10
In this week's M&A review
* Bluebird bio to be acquired by Carlyle and SK Capital
Bluebird bio to be acquired by Carlyle and SK Capital
According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital
A US$ 250 million Play for Spinal Stimulation Patents
Globus Medical announced its US$ 250 million acquisition of Nevro on February 6, 2025, gaining control of their large spinal cord stimulation (SCS) patent portfolio.
This acquisition expands Globus' neuromodulation patent portfolio and strengthens its position in the US$13.3 billion spinal device market. A market that is